Behavioral and Brain Functions

Table 4 Gene-gene and gene-treatment interaction for smoking cessation in 593 women, Seattle, WA, 1993–1998.

From: Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study

	Short-term Quit						Long-term Quit
	Quit		Did not quit				Quit		Did not quit
	N	%	N	%	RR	95% CI	N	%	N	%	RR	95% CI
	DRD2 Taq1 A2/A2
SLC6A3
no 9-repeats	45	60.0	164	58.2	1.0	Ref	38	62.3	181	57.6	1.0	Ref
one or two 9-repeats	39	40.0	118	41.8	0.9	0.6, 1.4	23	37.7	133	43.4	0.8	0.5, 1.4
	DRD2 Taq1 A1/A2 or A1/A1
SLC6A3
no 9-repeats	12	32.4	95	58.8	1.0	Ref	12	40.0	101	57.4	1.0	Ref
one or two 9-repeats	25	67.6	64	40.2	2.5	1.3, 4.7	18	60.0	75	42.6	1.8	0.9, 3.6
	DRD3 Ser/Ser
Arm
Placebo	26	49.1	96	51.1	1.0	Ref	23	51.1	111	52.6	1.0	Ref
D,1-fenfluramine	27	50.9	92	48.9	1.1	0.7, 1.7	22	48.9	100	47.4	1.1	0.6, 1.8
	DRD3 Ser/Gly and Gly/Gly
Arm
Placebo	33	53.2	124	48.4	1.0	Ref	19	39.6	146	51.4	1.0	Ref
D,1-fenfluramine	29	46.8	132	51.6	0.9	0.5, 1.3	29	60.4	138	48.6	1.5	0.9, 2.6
	DRD4 short/short
Arm
Placebo	32	45.1	118	46.1	1.0	Ref	18	34.0	145	50.0	1.0	Ref
D,1-fenfluramine	39	54.9	138	53.9	1.0	0.7, 1.6	35	66.0	145	50.0	1.8	1.0, 3.0
	DRD4 short/long and long/long
Arm
Placebo	26	61.9	97	54.2	1.0	Ref	24	61.5	106	54.9	1.0	Ref
D,1-fenfluramine	16	38.1	82	45.8	0.8	0.4, 1.4	15	38.5	87	45.1	0.8	0.4, 1.4

Back to article page

ISSN: 1744-9081

Contact us

Submission enquiries: journalsubmissions@springernature.com